Through coordinated GLP-1R and GIPR activation, tirzepatide enhances glucose-dependent insulin secretion, improves glycemic control, contributes to lipid homeostasis, and reduces appetite and food intake, supporting its clinical use in obesity and type 2 diabetes [13]
Yet you still feel like garbage
Retatrutide, a newer triple agonist targeting GIP, GLP-1, and glucagon receptors, has a half-life of approximately six days
Ten units on an insulin syringe equals 0.1 mL of liquid
Shop by Health Benefits Discover our doctor-formulated products collections designed to provide targeted nutritional support for your longevity, optimal health and energy management